Gene | SNP | Fatty acid | Genotype | No recent aspirin/NSAID use | Recent aspirin/NSAID use | ||
---|---|---|---|---|---|---|---|
Low | High | Low | High | ||||
ORa (95Â % CI) | ORa (95Â % CI) | ORa (95Â % CI) | ORa (95Â % CI) | ||||
PTGS1 | rs1330344 (−1,676 T > C9 | 22:06 | AA | 1 | 0.97 (0.68, 1.39) | 1 | 0.63 (0.41, 0.98) |
 | AG/GG | 1.08 (0.74, 1.58) | 0.81 (0.54, 1.21) | 0.57 (0.35, 0.91) | 1.21 (0.76, 1.91) | ||
 | p-interaction (2-way)a |  | 0.34 | 0.0003 |  | ||
 | p-interaction (3-way)a |  | 0.001 |  |  | ||
rs10306122 (2,125 TÂ >Â C) | PUFA | AA | 1 | 0.99 (0.69, 1.43) | 1 | 0.84 (0.55, 1.30) | |
 | AG/GG | 2.17 (1.13, 4.14) | 0.61 (0.35, 1.06) | 1.11 (0.51, 2.40) | 1.07 (0.58, 1.99) | ||
 | p-interaction (2-way)a |  | 0.002 | 0.77 |  | ||
 | p-interaction (3-way)a |  | 0.02 |  |  | ||
18:02 | AA | 1 | 1.01 (0.70, 1.46) | 1 | 0.86 (0.56, 1.33) | ||
 | AG/GG | 2.23 (1.17, 4.24) | 0.61 (0.35, 1.05) | 1.2 (0.56, 2.57) | 1.05 (0.56, 1.97) | ||
 | p-interaction (2-way)a |  | 0.0009 | 0.97 |  | ||
 | p-interaction (3-way)a |  | 0.03 |  |  |